* Humanigen Inc HGEN.OQ HGEN.O is expected to show a
fall in
quarterly revenue when it reports results on May 3
(estimated).
*
* Refinitiv's mean analyst estimate for Humanigen Inc is
for a
loss of 6 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Humanigen
Inc is
$0.33, above its last closing price of $0.16.
This summary was machine generated May 1 at 11:19 GMT. All
figures in US dollars unless otherwise stated